Singapore’s NGS-based RNA-sequencing Market, valued at US$ XX billion in 2024 and 2025, is expected to grow steadily at a CAGR of XX% from 2025–2030, reaching US$ XX billion by 2030.
Global NGS-based RNA-sequencing market, reached $2.5B in 2022, and is projected to grow at a robust 17.2% CAGR, hitting $5.5B by 2027.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=102977816
Drivers
The Singapore NGS-based RNA-sequencing market is substantially driven by the nation’s significant and sustained investment in precision medicine and advanced biomedical research. The government, through initiatives like the National Precision Medicine (NPM) program, actively fosters the integration of genomic technologies, creating a high demand for sophisticated tools like RNA sequencing to understand complex disease mechanisms and develop targeted therapies. Furthermore, the decreasing cost of sequencing technologies globally, coupled with the inherent advantages of RNA sequencing over conventional gene expression analysis methods—such as its ability to quantify novel transcripts and fusion genes—accelerates its adoption across Singapore’s numerous academic institutions, research hospitals, and pharmaceutical companies. The high incidence of chronic diseases and cancer in the aging population necessitates advanced diagnostic and prognostic tools, where RNA-seq’s utility in identifying biomarkers and monitoring treatment response is critical. Singapore’s highly skilled scientific workforce and world-class research infrastructure also provide a fertile ecosystem for the rapid uptake and application of these advanced sequencing techniques, solidifying its position as a regional hub for transcriptomics research.
Restraints
Despite the strong drivers, the Singapore NGS-based RNA-sequencing market faces considerable restraints, particularly concerning cost, data management, and standardization. The initial capital expenditure for acquiring and maintaining high-throughput NGS platforms and the associated computational infrastructure remains significant, which can limit widespread adoption, especially among smaller research labs or clinical facilities. A major technical and operational restraint is the standardization of RNA-sequencing protocols in clinical diagnostic settings. Ensuring consistent sample preparation, data quality, and assay reliability across different institutions and batches is challenging, leading to concerns over reproducibility and regulatory acceptance. Additionally, the sheer volume and complexity of the sequencing data generated necessitate robust data storage, secure management systems, and specialized bioinformatics expertise for interpretation, which is a resource-intensive bottleneck in Singapore. While the cost of sequencing is decreasing, the expenses associated with data analysis and the shortage of personnel proficient in both transcriptomics and data science continue to act as key restraining factors for full market penetration.
Opportunities
Significant opportunities are emerging within the Singapore NGS-based RNA-sequencing market, primarily fueled by applications in personalized medicine, clinical diagnostics, and strategic collaborations. The shift towards personalized therapeutics offers a major opportunity, as RNA-seq is essential for analyzing the transcriptome to tailor treatments based on individual molecular profiles, particularly in oncology and infectious disease management. The growing momentum in liquid biopsy, where RNA-seq can be applied to circulating tumor RNA for non-invasive cancer monitoring, presents a high-growth segment. Furthermore, Singapore’s strong pharmaceutical and biotech sector creates opportunities for partnerships between local technology developers and multinational companies for commercializing innovative RNA-sequencing-based diagnostic assays. There is untapped potential in expanding RNA-seq applications beyond human health into areas like synthetic biology and agricultural genomics, leveraging Singapore’s expertise in advanced manufacturing and life sciences. The adoption of cloud computing and blockchain technologies for secure data sharing and collaborative research, as identified in global trends, presents an opportunity to overcome local data management challenges and accelerate multi-institutional studies.
Challenges
The Singapore NGS-based RNA-sequencing market must navigate several critical challenges to ensure sustainable growth. A primary hurdle is the complexity of data interpretation, specifically translating raw sequencing data into clinically actionable insights. This requires highly sophisticated bioinformatics tools and skilled personnel, which remain scarce resources. Technical challenges persist in achieving high-quality sequencing results from low-input or highly fragmented RNA samples, such as those derived from formalin-fixed, paraffin-embedded (FFPE) tissues, commonly used in pathology. Furthermore, maintaining a competitive edge against established global sequencing hubs requires continuous innovation and investment to prevent talent outflow and secure a sufficient volume of large-scale genomic projects. Regulatory compliance and ethical considerations surrounding the use and sharing of genomic data are also complex challenges that require clear guidelines and robust technological frameworks for data privacy and security. Addressing these challenges demands coordinated efforts between government, industry, and academia to streamline protocols, enhance bioinformatics capacity, and foster public trust in genomic data utilization.
Role of AI
Artificial Intelligence (AI) is instrumental in unlocking the full potential of Singapore’s NGS-based RNA-sequencing market. AI and machine learning algorithms are essential for managing and interpreting the massive datasets generated by RNA-seq experiments, automating tasks such as read alignment, transcriptome assembly, and differential expression analysis much faster and more accurately than traditional methods. In clinical settings, AI models can analyze complex RNA signatures to classify diseases, predict patient outcomes, and identify novel biomarkers, significantly enhancing the diagnostic utility of RNA-seq. For drug discovery, AI-driven analysis of RNA-seq data from high-throughput screens or organ-on-a-chip models can rapidly pinpoint therapeutic targets and predict compound efficacy and toxicity, accelerating the research pipeline. Singapore’s national commitment to AI integration within healthcare provides a strong institutional backbone for this synergy. The combination of high-resolution RNA-sequencing hardware with intelligent AI software allows researchers and clinicians to extract deeper biological meaning, transforming raw genomic data into precise, actionable clinical and translational insights.
Latest Trends
Several latest trends are defining the future trajectory of the Singapore NGS-based RNA-sequencing market. A major trend is the accelerated adoption of single-cell RNA sequencing (scRNA-seq), which allows for transcriptional profiling at the resolution of individual cells, providing unprecedented insight into cellular heterogeneity, particularly in cancer and immunology research. This is highly relevant in Singapore’s precision medicine push. Another growing trend is the convergence of NGS-based RNA-seq with spatial transcriptomics, enabling researchers to map gene expression patterns within the original tissue context, adding critical anatomical resolution to molecular data. Furthermore, there is an increasing demand for automated, end-to-end RNA-sequencing library preparation and analysis systems to improve workflow efficiency and reduce human error, facilitating adoption in clinical laboratories. The rise of long-read sequencing technologies for full-length RNA sequencing, offering the ability to resolve complex isoforms, is also gaining traction. Lastly, the development of integrated bioinformatics solutions, often leveraging cloud computing and AI, is streamlining the data analysis pipeline, making sophisticated transcriptomic analysis more accessible to a broader range of clinical and research users across Singapore.